Pappachan, Lancashire Teaching Hospitals NHS Foundation Trust, United Kingdom Reviewed by Benjamin Ct Field, University of Surrey, United Kingdom Updates Copyright 2025 Resnick, Bril and Beauchamp
Medicare: Historically excluded weight-loss drugs
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a)
This approach has been validated extensively for accuracy and reproducibility in gastric content assessment [1121]
However, the natural role of the body's own brief burst of GLP-1 (a hormone made in the gut) has been hard to understand, mainly because it gets broken down so quickly that it barely reaches the pancreas
The purpose of this search was to uncover controlled trials that examined the impact of bupropion, either as a standalone intervention or in combination with naltrexone, on weight loss outcomes